MNPR vs. ABVC, ELAB, AKTX, AVTX, MIRA, MBRX, GHSI, AEZS, IMNN, and ERNA
Should you be buying Monopar Therapeutics stock or one of its competitors? The main competitors of Monopar Therapeutics include ABVC BioPharma (ABVC), Elevai Labs (ELAB), Akari Therapeutics (AKTX), Avalo Therapeutics (AVTX), MIRA Pharmaceuticals (MIRA), Moleculin Biotech (MBRX), Guardion Health Sciences (GHSI), Aeterna Zentaris (AEZS), Imunon (IMNN), and Eterna Therapeutics (ERNA). These companies are all part of the "pharmaceutical preparations" industry.
ABVC BioPharma (NASDAQ:ABVC) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, community ranking, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.
11.4% of ABVC BioPharma shares are held by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are held by institutional investors. 11.9% of ABVC BioPharma shares are held by company insiders. Comparatively, 41.6% of Monopar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Monopar Therapeutics received 39 more outperform votes than ABVC BioPharma when rated by MarketBeat users.
In the previous week, ABVC BioPharma had 3 more articles in the media than Monopar Therapeutics. MarketBeat recorded 4 mentions for ABVC BioPharma and 1 mentions for Monopar Therapeutics. ABVC BioPharma's average media sentiment score of -0.42 beat Monopar Therapeutics' score of -0.42 indicating that Monopar Therapeutics is being referred to more favorably in the news media.
Monopar Therapeutics has a consensus price target of $2.00, suggesting a potential upside of 227.87%. Given ABVC BioPharma's higher probable upside, analysts clearly believe Monopar Therapeutics is more favorable than ABVC BioPharma.
ABVC BioPharma has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500. Comparatively, Monopar Therapeutics has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500.
Monopar Therapeutics has a net margin of 0.00% compared to Monopar Therapeutics' net margin of -6,919.08%. ABVC BioPharma's return on equity of -110.42% beat Monopar Therapeutics' return on equity.
Monopar Therapeutics has lower revenue, but higher earnings than ABVC BioPharma. Monopar Therapeutics is trading at a lower price-to-earnings ratio than ABVC BioPharma, indicating that it is currently the more affordable of the two stocks.
Summary
Monopar Therapeutics beats ABVC BioPharma on 10 of the 15 factors compared between the two stocks.
Get Monopar Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MNPR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MNPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Monopar Therapeutics Competitors List
Related Companies and Tools
